Blogging at https://xitter.cf/t.co/fcSWIRe0LZ | Science @SNIPRBiome l Previous at the Novo Nordisk Foundation Center for Biosustainability in @Sommergroup | #synbio

Copenhagen, Denmark
Joined November 2011
Looking forward to meeting everyone is Lisbon!
We'll be at GAMRIC, the Global AMR Innovators Conference, in Lisbon next week, 22–24 September. @ESCMID 📅 Tue 22 Sept, 16:45–18:15: @EricvdHelm on the SNIPR001 Phase 1 results 📅 Wed 23 Sept , 13:00–14:00: @groendahl joins the panel discussion
121
In 2017 this was a plan on a whiteboard. Now it's 66 patients across ten sites.
First patient enrolled in Phase 2 of our SNIPR001 trial. The study expands to 66 patients across ten sites, now including Memorial Sloan Kettering and Dana-Farber. Read the full press release: static1.squarespace.com/stat… #PRESS
2
322
Last month, @groendahl and I joined @CARB_X Investor Day in Munich ahead of @ESCMID Global. Always energizing to be among so many teams pushing #AMR innovation forward; from early discovery to clinical-stage programs.
1
83
Proud to share our final positive Phase 1 results for SNIPR001 in @LancetMicrobe. Huge thanks to the @sniprbiome team & collaborators. We're using CRISPR to precisely target harmful E. coli bacteria in the gut - helping protect transplant patients from life-threatening infections
Today, we're excited to announce the publication of final Phase 1 results for SNIPR001, our CRISPR therapeutic designed to precisely reduce E. coli in the gut — including multi-drug resistant strains — while preserving healthy gut bacteria.
1
121
Looking forward to speak in Basel
We’re excited to share real-world lessons from building and translating CRISPR-based antimicrobials - what’s worked, what hasn’t, and what it takes to move from promise to patient impact at the 10th @AMR_Conference . Come meet @EricvdHelm in Basel.
1
98
Heading to London for the ⁦@Jefferies⁩ Global Healthcare Conference Nov 17–20. ⁦@sniprbiome⁩ will be on-site, together w. ⁦@groendahl⁩. We’re excited to share insights on our proprietary CRISPR platform and our differentiated #AMR pipeline. #JefferiesHealthcare
1
129
I couldn’t be prouder of the SNIPR team today! We’ve just closed a €35 million Series B to push the boundaries of antimicrobial therapy. Huge thanks to our investors, partners, and team members that were part of this journey.
We proudly announced the close of a €35 million Series B financing! Learn more about this milestone in the press release below. #AMR #CRISPR #SeriesB
1
129
Very proud to see our lead asset now being dosed in patients for the first time. Big congrats to the whole team!
📢 SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer— the first CRISPR-armed phage therapeutic designed to target E. coli in the gut. @CARB_X
100
Eric van der Helm retweeted
Looking forward to meeting at #BIO2025! Reach out if you'd like to connect with @groendahl and @EricvdHelm in Boston June 16-19. DM here or email [email protected]
1
99
Eric van der Helm retweeted
Replying to @groendahl
@groendahl and @EricvdHelm will be attending next week's #BioEquity in Bruges🇧🇪. Reach out to learn more about our recent progress and updates of our pipeline. #partnering #BioEquityEurope
1
76
I’m looking forward to meeting everyone in Berlin next week, so if you’re also attending @SPRIND feel free to send me a message
Meet SNIPR BIOME next week: Jakob & @EricvdHelm at Venture @SPRIND Berlin (Apr 8), Alice discussing untreatable infections at EU Parliament, and @groendahl & Anders at #ESCMIDGLOBAL Vienna (Apr 10-14). Don't miss our SNIPR001 poster (P2537) Apr 13, 12:00–13:30, Hall D!
111
Eric van der Helm retweeted
SNIPR Biome strengthens IP portfolio with a patent granted for a novel #CRISPR-Cas system! Read more in the press release below.
1
1
2
240
Eric van der Helm retweeted
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases. I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known. People can contact me directly at my first name (as written in my profile) at octant.bio.
977
5,232
205
18,774
2,658,017
On February 25-26, @groendahl and I will be in Basel for the #AMRConference. We’re excited to discuss how @sniprbiome CRISPR technology can help combat #AntimicrobialResistance. If you're attending, feel free to reach out via [email protected]
1
6
279
Eric van der Helm retweeted
Attending #JPM2025 this January? @groendahl and @EricvdHelm will be present and involved in JPM week events. Reach out if you want to meet in San Francisco!
1
219
Seven days to #BioEurope! Reach out if you are at #BioEurope and want to know more about @sniprbiome progress in AMR and Microbial Gene Therapy.
1
170
Want to know more about building large #phage libraries using cell-free synthesis? Check out our new @sniprbiome scientific article in @OUPSynBio. Big congrats to PhD student Camilla Schoopp Kristensen for leading this work.
🧬 New publication alert! Our team has just published a new article on advancing bacteriophage engineering in the @OUPSynBio. Congratulations to authors Camilla Kristensen, Anders Østergaard, Mogens Kilstrup (@DTUbioengineer), @EricvdHelm & Adam Takos. doi.org/10.1093/synbio/ysae0…
4
429
Great to see David Baker’s groundbreaking work recognized with the 2024 Nobel Prize in Chemistry. It was an incredible experience to have worked in his lab at the @UWproteindesign over a decade ago and to see the work he's been honored for today!
BREAKING NEWS The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”
1
169
Eric van der Helm retweeted
We are pleased to share that SNIPR Biome has received funding from the @gatesfoundation to advance our microbial gene therapy platform aimed at improving Environmental Enteric Dysfunction in pregnant women from low- and middle-income countries (LMICs). static1.squarespace.com/stat…
1
8
486
Eric van der Helm retweeted
One of the many perks as an Unveil Bio customer: Edible plasmids! Get your plasmids sequenced at eu1.hubs.ly/H09t7x-0
1
2
83